Glycoscientific, L.L.C.

Athens, GA

UEI
EUVNNWGFCA87
CAGE
5CAT5
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
Center for Applied Genetic TECHNOLOGIES, 111 Riverbend Rd rm 261, Athens, GA 30602, USA
Founded
2009
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 $0
FY2023 $600,000

Contract awards

Award Agency Obligated Awarded
Sbir topic 118: reagents for immunologic analysis of non-mammalian and underrepresented mammalian models. 75N93023C00038 National Institute of Allergy and Infectious Diseases (NIH) $600,000
068, creating antibodies to enable the study of mycobacterium tuberculosis infections in guinea pigs 75N93019C00048 National Institute of Allergy and Infectious Diseases (NIH) $653,191
Sbir topic 294 phase I - development of glycosylation-specific research reagents (antibodies and aptamers) HHSN261201100074C National Cancer Institute (NIH) $149,951

Grant awards

Award Agency Obligated Awarded
Recognition of O-glcnac modified proteins using site-specific antibodies - pulmonary arterial HYPERTENSION (PAH) is a… R43HL166086 National Heart Lung and Blood Institute (NIH) $275,767
Isotopically labeled heparan sulfate glycosaminoglycan disaccharides for use as internal standards R41GM139440 National Institute of General Medical Sciences (NIH) $252,114
Development of site-specific ARG-glcnac antibodies R43GM133288 National Institute of General Medical Sciences (NIH) $298,483
Generation of antibodies to monitor notch O-fucosylation in vivo R41GM119879 National Institute of General Medical Sciences (NIH) $242,306
Development of isotopically labeled glycoproteins for use as internal standards R42GM113666 National Institute of General Medical Sciences (NIH) $1,385,997

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Natglycan LLC UEI NMMMHXNPL8U5 Tucker, GA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Biotechnology Research UEI KYG3DZSMH4R7 Raleigh, NC 325414 Biological Product (except Diagnostic) Manufacturing
Z Biotech, LLC UEI KTUKAUTZVRJ3 Aurora, CO 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Lectenz Bio, Inc. UEI JTGCK219C6F4 Athens, GA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
IHP Therapeutics Inc. UEI MASZJLS7DHK3 San Carlos, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Glycoscientific, L.L.C., doing business as Glycoscientific LLC, is a research company and producer of standard reagents for glycan analysis and other glycobiology research. The company is developing tools to enable research in glycobiology, which focuses on the identification, characterization, and quantification of glycans and glycoconjugates.

Glycoscientific has been awarded federal contracts from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases to provide reagents for immunologic analysis of non-mammalian and underrepresented mammalian models, as well as to enable the study of Mycobacterium tuberculosis infections in guinea pigs. These contracts were set aside for total small businesses and had potential values ranging from $600,000 to $653,191.

Glycoscientific has also received federal grants from NIH entities including the National Heart Lung and Blood Institute and the National Institute of General Medical Sciences. These grants funded the development of site-specific antibodies to recognize peptide sequences modified by O-GlcNAc glycosylation in order to study pulmonary arterial hypertension, as well as the production of isotopically labeled heparan sulfate glycosaminoglycan disaccharides for use as internal standards. The grants ranged in value from $252,114 to $298,483.

Quick answers

Is Glycoscientific, L.L.C. registered in SAM.gov?

Yes. Glycoscientific, L.L.C.'s SAM.gov registration is active through August 25, 2027.

What is Glycoscientific, L.L.C.'s CAGE code?

Glycoscientific, L.L.C.'s CAGE code is 5CAT5, and its Unique Entity ID (UEI) is EUVNNWGFCA87.

How much has Glycoscientific, L.L.C. received in federal contracts?

Federal contracts obligated $600,000 to Glycoscientific, L.L.C. in fiscal years 2023 through 2027.

What is Glycoscientific, L.L.C.'s most recent federal award?

Glycoscientific, L.L.C.'s most recent federal contract award is Sbir topic 118: reagents for immunologic analysis of non-mammalian and underrepresented mammalian models (75N93023C00038), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2023.

On GovTribe

See Glycoscientific, L.L.C.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe